

**Tabla suplementaria:** Estudios excluidos, por motivos de exclusión.

Motivo exclusión	Estudio	
No realizan subanálisis de obesidad	Adebajo, 2014 <sup>1</sup>	Metyas, 2016 <sup>7</sup>
	Di Minno, 2013 <sup>2</sup>	Nash, 2016 <sup>8</sup>
	Di Minno, 2014 <sup>3</sup>	Nash, 2018 <sup>9</sup>
	Gisoni, 2015 <sup>4</sup>	Paul, 2012 <sup>10</sup>
	Haugeberg, 2012 <sup>5</sup>	Pérez-Plaza, 2017 <sup>11</sup>
	Kivitz, 2018 <sup>6</sup>	Tsuji, 2015 <sup>12</sup>
Desenlace o diseño no adecuado	Eberle, 2010 <sup>13</sup>	Koehm, 2013 <sup>24</sup>
	Haroon, 2013 <sup>14</sup>	Kwan, 2017 <sup>25</sup>
	Haroon, 2014 <sup>15</sup>	McInnes, 2011 <sup>26</sup>
	Haroon, 2014 <sub>b</sub> <sup>16</sup>	Menter, 2016 <sub>b</sub> <sup>27</sup>
	Helliwell, 2015 <sup>17</sup>	Migkos, 2017 <sup>28</sup>
	Hojgaard, 2016 <sup>*_b</sup> <sup>18</sup>	Renzo, 2011 <sup>29</sup>
	Husted, 2013 <sup>19</sup>	Sinnathurai, 2018 <sup>30</sup>
	Iannone, 2018 <sup>20+</sup>	Sethi, 2015 <sup>31</sup>
	Iervolino, 2012 <sup>21</sup>	Yamauchi, 2016 <sup>32</sup>
	Jamnitski, 2013 <sup>22</sup>	Zaffarana, 2016 <sup>33</sup>
	Klingberg, 2018 <sup>23</sup>	
	No realizan subanálisis de APs	Gagne, 2008 <sup>34</sup>
Garcia-Doval, 2016 <sup>35</sup>		Lebwohl, 2010 <sup>41</sup>
Jacobi, 2016 <sup>36</sup>		Mahé, 2015 <sup>42</sup>
Jensen, 2013 <sup>37</sup>		Mandema, 2013 <sup>43</sup>
Jensen, 2014 <sup>38</sup>		Saraceno, 2008 <sup>44</sup>
Karray, 2016 <sup>39</sup>		
RS con trabajos ya revisados en este estudio	Almodovar, 2018 <sup>45</sup>	Lupoli, 2016 <sup>48</sup>
	Galindez, 2016 <sup>46</sup>	Shan, 2018 <sup>49</sup>
	Gallo, 2018 <sup>47</sup>	Singh, 2018 <sup>50</sup>

Abreviaturas: APs= artritis Psoriásica

\*: Datos incluidos en el estudio en Hojgaard\_2016<sup>51</sup>

†: En el apartado de métodos, determinan que se hace análisis por peso, pero no está reflejado dicho valor en los resultados

1. Adebajo A, Wells A, Edwards C, Kivitz A, Bird P, Shah K, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: A phase 3, randomized, controlled trial. *Annals of the Rheumatic Diseases*. 2014;73.
2. Di Minno MND, Iervolino S, Peluso R, Lupoli R, Russolillo A, Bottiglieri P, et al. Weight loss and induction of minimal disease activity in psoriatic arthritis patients starting TNF- $\alpha$  blockers treatment. *Annals of the Rheumatic Disease*. 2013;71.
3. Di Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor  $\alpha$  blockers. *Annals of the Rheumatic Diseases*. 2014;73(6):1157-62.
4. Gisoni P. Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register. *British Journal of Dermatology*. 2015;173(2):329-30.

5. Haugeberg G, Diamantopoulos A, Soldal DM, Kavanaugh A. Disease activity, health status, and treatment in unselected psoriatic arthritis patients from an ordinary outpatient clinic in Norway. *Scandinavian Journal of Rheumatology*. 2012;41:62-3.
6. Kivitz A, Nash P, Tahir H, Everding A, Pellet P, Widmer A, et al. Arthritis: Primary results through 52 weeks from a phase-3 randomized placebo-controlled study (future 4). *Journal of Clinical Rheumatology*. 2018;24(3):S1-S2.
7. Metyas S, Messiah R, Gettas T, Asfahani L, Quismorio A. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. *Arthritis and Rheumatology*. 2016;68:2166.
8. Nash P, McInnes IB, Mease P, Thom H, Cure S, Palaka E, et al. Secukinumab for the treatment of psoriatic arthritis: Comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison. *Annals of the Rheumatic Diseases*. 2016;75:353-4.
9. Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, et al. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. *Rheumatol Ther*. 2018;5(1):99-122.
10. Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaci D. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. *Eur J Dermatol*. 2012;22(6):762-9.
11. Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, et al. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. *Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology*. 2017;31(6):1021-8.
12. Tsuji S, Higashiyama M, Tomita T, Matsui M, Tsuboi H, Hashimoto J. Predictors of minimal disease activity in patients treated with adalimumab for 52 weeks in clinical practice. *Annals of the Rheumatic Diseases*. 2015;74:871.
13. Eberle E, Knight E, Raddatz DA, Messing S, Reed G, Greenberg JD, et al. Association of BMI and Psoriatic arthritis disease activity. *Arthritis and Rheumatism*. 2010;62:515.
14. Haroon M, Petty-Saphon N, Gallagher P, FitzGerald O. Clinical and patient-reported outcome measures as predictors of poor functional outcome in psoriatic arthritis. *Annals of the Rheumatic Diseases*. 2013;72.
15. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome is associated with the severity of underlying psoriatic arthritis. *Irish Journal of Medical Science*. 2014;183(3):S103.
16. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. *J Rheumatol*. 2014;41(7):1357-65.
17. Helliwell P, Jones H, Hsu MA, Szumski A, Peifer K, Chhabra A. Effect of etanercept on patient-reported outcomes in psoriasis patients with and without metabolic syndrome. *Journal of Investigative Dermatology*. 2015;135:S36.
18. Højgaard P, Glintborg B, Kristensen LE, Love TJ, Gudbjornsson B, Dreyer L. Obesity impairs the response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: Results from the DANBIO and ICEBIO registries. *Annals of the Rheumatic Diseases*. 2016;75:340.
19. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. *Journal of Rheumatology*. 2013;40(8):1349-56.
20. Iannone F, Santo L, Bucci R, Semeraro A, Carlino G, Paoletti F, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). *Clin Rheumatol*. 2018;37(3):667-75.

21. Iervolino S, Di Minno MND, Peluso R, Lofrano M, Russolillo A, Di Minno G, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor- $\alpha$  blockers. *Journal of Rheumatology*. 2012;39(3):568-73.
22. Jamnitski A, Symmons D, Peters MJL, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. *Annals of the Rheumatic Diseases*. 2013;72(2):211-6.
23. Klingberg E, Bilberg A, Björkman S, Eliasson B, Larsson I. Weight-loss improves disease activity in obese patients with psoriatic arthritis. *Annals of the Rheumatic Diseases*. 2018;77:1029.
24. Koehm M, Behrens F, Thaci D, Krummel-Lorenz B, Greger G, Wittig B, et al. Differences in disease characteristics of patients with active psoriatic arthritis prior to adalimumab treatment who failed at least two anti-TNF-therapies in comparison to those who failed conventional DMARDs only. *Annals of the Rheumatic Diseases*. 2013;72.
25. Kwan YH, Lee YX, Lim KK, Tan CS, Lui NL, Chew EH, et al. A systematic review of the association between obesity and outcome of rheumatic diseases. *Value in Health*. 2017;20(5):A150.
26. McInnes I, Sieper J, Braun J, Emery P, Van Der Heijde D, Isaacs J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. *Arthritis and Rheumatism*. 2011;63(10).
27. Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, et al. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials. *J Drugs Dermatol*. 2016;15(5):568-80.
28. Migkos MP, Memi TE, Markatseli TE, Drosos AA, Voulgari PV. Clinical manifestations and parameters affecting therapeutic response in a cohort of 411 psoriatic arthritis patients. *Annals of the Rheumatic Diseases*. 2017;76:1329.
29. Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF- $\alpha$  treatment. *Dermatol Ther*. 2011;24(4):446-51.
30. Sinnathurai P, Xue M, March L. Obesity and disease activity in psoriatic arthritis: Preliminary data from a prospective psoriatic arthritis cohort study. *Internal Medicine Journal*. 2018;48:16.
31. Sethi M, Ren-Fielding C, Lee S, Schwack B, Kurian M, Fielding G, et al. Improvements in psoriasis and psoriatic arthritis with surgical weight loss. *Surgery for Obesity and Related Diseases*. 2015;11(6):S64-S5.
32. Yamauchi P, Maa JF, Valdecantos W. Baseline demographics and disease characteristics of long-term responders to adalimumab in reveal. *Journal of the European Academy of Dermatology and Venereology*. 2016;30:75-6.
33. Zaffarana C, Yanzi JG, Cerda OL, Landi M, Schneeberger E, Citera G. Prevalence of obesity in patients with psoriatic arthritis and its impact on the severity of the disease. *Arthritis and Rheumatology*. 2016;68:3715-6.
34. Gagné DJ, Papasavas PK, Dovec EA, Urbandt JE, Caushaj PF. Effect of immunosuppression on patients undergoing bariatric surgery. *Surgery for Obesity and Related Diseases*. 2009;5(3):339-45.
35. García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, De La Cueva P, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. *Journal of Dermatological Treatment*. 2016;27(3):203-9.
36. Jacobi A, Rustenbach SJ, Augustin M. Persistence of biologic therapy in psoriasis patients with comorbidity. *Journal of the American Academy of Dermatology*. 2016;74(5):AB262.

37. Jensen P, Zachariae C, Christensen R, Geiker N, Schaadt B, Stender S, et al. Effect of weight loss on the severity of psoriasis: A randomised controlled trial. *Journal of Investigative Dermatology*. 2013;133:S182.
38. Jensen P, Zachariae C, Christensen R, Geiker NRW, Schaadt BK, Stender S, et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. *Acta Dermato-Venereologica*. 2014;94(6):691-4.
39. Karray M, Youssef S, Alkathiri M, Alaoui F, Abdelhedi N, Jaber K, et al. Impact of body mass index on psoriasis in Tunisian patients. *Journal of the European Academy of Dermatology and Venereology*. 2016;30:44.
40. Kimball AB, Alavian C, Alora-Palli M, Bagel J. Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. *Journal of the European Academy of Dermatology and Venereology*. 2012;26(12):1582-4.
41. Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. *Journal of the American Academy of Dermatology*. 2010;63(4):571-9.
42. Mahé E, Beauchet A, Bodemer C, Phan A, Bursztejn AC, Boralevi F, et al. Psoriasis and obesity in French children: A case-control, multicentre study. *British Journal of Dermatology*. 2015;172(6):1593-600.
43. Mandema J, Peterson M, Ahadieh S, Tan H, Krishnaswami S, Wolk R, et al. Evaluation of the impact of body weight on the efficacy of biologic therapies for the treatment of psoriasis: A dose-response meta-analysis. *Journal of the European Academy of Dermatology and Venereology*. 2013;27:11-2.
44. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, et al. Effect of anti-tumor necrosis factor- $\alpha$  therapies on body mass index in patients with psoriasis. *Pharmacological Research*. 2008;57(4):290-5.
45. Almodovar R, Zarco P, Oton T, Carmona L. Effect of weight loss on activity in psoriatic arthritis: A systematic review. *Reumatol Clin*. 2018;14(4):207-10.
46. Galíndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? *Reumatología Clínica*. 2016;12(6):307-12.
47. Gallo G, Candilio G, De Luca E, Iannicelli A, Sciaudone G, Pellino G, et al. Bariatric Surgery and Rheumatic Diseases: A Literature Review. *Rev Recent Clin Trials*. 2018;13(3):176-83.
48. Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: A systematic review and meta-analysis. *Arthritis Research and Therapy*. 2016;18(1).
49. Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. *Joint Bone Spine*. 2018.
50. Singh S, Facciorusso A, Singh AG, Castele NV, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. *PLoS One*. 2018;13(5):e0195123.
51. Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. *Rheumatology (Oxford)*. 2016;55(12):2191-9.